Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy

Sangnae Cho, R. V. Cellona, L. G. Villahermosa, Jr Fajardo, M. V.F. Balagon, R. M. Abalos, E. V. Tan, G. P. Walsh, J. D. Kim, P. J. Brennan

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

A total of 100 untreated new leprosy patients were recruited prospectively and examined for the presence of phenolic glycolipid I (PGL-I) antigen in their serum specimens by dot enzyme-linked immunosorbent assay (ELISA) using rabbit anti-PGL-I antiserum. The presence of circulating PGL-I antigen was closely related to the bacterial indices (BI) of the patients. The PGL-I antigen was detectable in 27 (93.1%) of 29 patients with a BI of 4.0 or above and in 15 (68.2%) of 22 patients with a BI of 3.0 to 3.9. However, none of the 37 patients with a BI of less than 1.9 had detectable PGL-I antigen by the methods used in this study. The level of PGL-I in serum declined rapidly by about 90% 1 month after the start of multidrug therapy. This study showed clearly that anti-PGL-I IgM antibodies and circulating PGL-I antigen levels reflect the bacterial loads in untreated leprosy patients. The serological parameters based on the PGL-I antigen may therefore be useful in them assessment of leprosy patients at the time of diagnosis and possibly in monitoring patients following chemotherapy.

Original languageEnglish
Pages (from-to)138-142
Number of pages5
JournalClinical and Diagnostic Laboratory Immunology
Volume8
Issue number1
DOIs
Publication statusPublished - 2001 Feb 1

Fingerprint

Glycolipids
Leprosy
Serum
Therapeutics
Mycobacterium leprae phenolic glycolipid I
Patient monitoring
Immunosorbents
Chemotherapy
Bacterial Load
Physiologic Monitoring
Immunoglobulin M
I-antigen
Immune Sera
Assays
Enzyme-Linked Immunosorbent Assay
Rabbits
Drug Therapy
Antibodies
Enzymes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Cho, Sangnae ; Cellona, R. V. ; Villahermosa, L. G. ; Fajardo, Jr ; Balagon, M. V.F. ; Abalos, R. M. ; Tan, E. V. ; Walsh, G. P. ; Kim, J. D. ; Brennan, P. J. / Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy. In: Clinical and Diagnostic Laboratory Immunology. 2001 ; Vol. 8, No. 1. pp. 138-142.
@article{a12ab9a025ac405fb0ce42349d1eb6aa,
title = "Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy",
abstract = "A total of 100 untreated new leprosy patients were recruited prospectively and examined for the presence of phenolic glycolipid I (PGL-I) antigen in their serum specimens by dot enzyme-linked immunosorbent assay (ELISA) using rabbit anti-PGL-I antiserum. The presence of circulating PGL-I antigen was closely related to the bacterial indices (BI) of the patients. The PGL-I antigen was detectable in 27 (93.1{\%}) of 29 patients with a BI of 4.0 or above and in 15 (68.2{\%}) of 22 patients with a BI of 3.0 to 3.9. However, none of the 37 patients with a BI of less than 1.9 had detectable PGL-I antigen by the methods used in this study. The level of PGL-I in serum declined rapidly by about 90{\%} 1 month after the start of multidrug therapy. This study showed clearly that anti-PGL-I IgM antibodies and circulating PGL-I antigen levels reflect the bacterial loads in untreated leprosy patients. The serological parameters based on the PGL-I antigen may therefore be useful in them assessment of leprosy patients at the time of diagnosis and possibly in monitoring patients following chemotherapy.",
author = "Sangnae Cho and Cellona, {R. V.} and Villahermosa, {L. G.} and Jr Fajardo and Balagon, {M. V.F.} and Abalos, {R. M.} and Tan, {E. V.} and Walsh, {G. P.} and Kim, {J. D.} and Brennan, {P. J.}",
year = "2001",
month = "2",
day = "1",
doi = "10.1128/CDLI.8.1.138-142.2001",
language = "English",
volume = "8",
pages = "138--142",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "1",

}

Cho, S, Cellona, RV, Villahermosa, LG, Fajardo, J, Balagon, MVF, Abalos, RM, Tan, EV, Walsh, GP, Kim, JD & Brennan, PJ 2001, 'Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy', Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 1, pp. 138-142. https://doi.org/10.1128/CDLI.8.1.138-142.2001

Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy. / Cho, Sangnae; Cellona, R. V.; Villahermosa, L. G.; Fajardo, Jr; Balagon, M. V.F.; Abalos, R. M.; Tan, E. V.; Walsh, G. P.; Kim, J. D.; Brennan, P. J.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 8, No. 1, 01.02.2001, p. 138-142.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy

AU - Cho, Sangnae

AU - Cellona, R. V.

AU - Villahermosa, L. G.

AU - Fajardo, Jr

AU - Balagon, M. V.F.

AU - Abalos, R. M.

AU - Tan, E. V.

AU - Walsh, G. P.

AU - Kim, J. D.

AU - Brennan, P. J.

PY - 2001/2/1

Y1 - 2001/2/1

N2 - A total of 100 untreated new leprosy patients were recruited prospectively and examined for the presence of phenolic glycolipid I (PGL-I) antigen in their serum specimens by dot enzyme-linked immunosorbent assay (ELISA) using rabbit anti-PGL-I antiserum. The presence of circulating PGL-I antigen was closely related to the bacterial indices (BI) of the patients. The PGL-I antigen was detectable in 27 (93.1%) of 29 patients with a BI of 4.0 or above and in 15 (68.2%) of 22 patients with a BI of 3.0 to 3.9. However, none of the 37 patients with a BI of less than 1.9 had detectable PGL-I antigen by the methods used in this study. The level of PGL-I in serum declined rapidly by about 90% 1 month after the start of multidrug therapy. This study showed clearly that anti-PGL-I IgM antibodies and circulating PGL-I antigen levels reflect the bacterial loads in untreated leprosy patients. The serological parameters based on the PGL-I antigen may therefore be useful in them assessment of leprosy patients at the time of diagnosis and possibly in monitoring patients following chemotherapy.

AB - A total of 100 untreated new leprosy patients were recruited prospectively and examined for the presence of phenolic glycolipid I (PGL-I) antigen in their serum specimens by dot enzyme-linked immunosorbent assay (ELISA) using rabbit anti-PGL-I antiserum. The presence of circulating PGL-I antigen was closely related to the bacterial indices (BI) of the patients. The PGL-I antigen was detectable in 27 (93.1%) of 29 patients with a BI of 4.0 or above and in 15 (68.2%) of 22 patients with a BI of 3.0 to 3.9. However, none of the 37 patients with a BI of less than 1.9 had detectable PGL-I antigen by the methods used in this study. The level of PGL-I in serum declined rapidly by about 90% 1 month after the start of multidrug therapy. This study showed clearly that anti-PGL-I IgM antibodies and circulating PGL-I antigen levels reflect the bacterial loads in untreated leprosy patients. The serological parameters based on the PGL-I antigen may therefore be useful in them assessment of leprosy patients at the time of diagnosis and possibly in monitoring patients following chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0035152323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035152323&partnerID=8YFLogxK

U2 - 10.1128/CDLI.8.1.138-142.2001

DO - 10.1128/CDLI.8.1.138-142.2001

M3 - Article

VL - 8

SP - 138

EP - 142

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 1

ER -